185 related articles for article (PubMed ID: 21196322)
21. Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway.
Chen Y; Tsai YH; Tseng SH
Surgery; 2013 Jan; 153(1):4-16. PubMed ID: 22703967
[TBL] [Abstract][Full Text] [Related]
22. MYCN gene expression is required for the onset of the differentiation programme in neuroblastoma cells.
Guglielmi L; Cinnella C; Nardella M; Maresca G; Valentini A; Mercanti D; Felsani A; D'Agnano I
Cell Death Dis; 2014 Feb; 5(2):e1081. PubMed ID: 24556696
[TBL] [Abstract][Full Text] [Related]
23. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.
Wang LL; Suganuma R; Ikegaki N; Tang X; Naranjo A; McGrady P; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Shimada H
Cancer; 2013 Oct; 119(20):3718-26. PubMed ID: 23901000
[TBL] [Abstract][Full Text] [Related]
24. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.
Kang JH; Rychahou PG; Ishola TA; Qiao J; Evers BM; Chung DH
Biochem Biophys Res Commun; 2006 Dec; 351(1):192-7. PubMed ID: 17055458
[TBL] [Abstract][Full Text] [Related]
25. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
[TBL] [Abstract][Full Text] [Related]
26. Inactivation of SMC2 shows a synergistic lethal response in MYCN-amplified neuroblastoma cells.
Murakami-Tonami Y; Kishida S; Takeuchi I; Katou Y; Maris JM; Ichikawa H; Kondo Y; Sekido Y; Shirahige K; Murakami H; Kadomatsu K
Cell Cycle; 2014; 13(7):1115-31. PubMed ID: 24553121
[TBL] [Abstract][Full Text] [Related]
27. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.
Regan PL; Jacobs J; Wang G; Torres J; Edo R; Friedmann J; Tang XX
Int J Oncol; 2011 Jan; 38(1):105-12. PubMed ID: 21109931
[TBL] [Abstract][Full Text] [Related]
28. Protein arginine methyltransferase 5 is a key regulator of the MYCN oncoprotein in neuroblastoma cells.
Park JH; Szemes M; Vieira GC; Melegh Z; Malik S; Heesom KJ; Von Wallwitz-Freitas L; Greenhough A; Brown KW; Zheng YG; Catchpoole D; Deery MJ; Malik K
Mol Oncol; 2015 Mar; 9(3):617-27. PubMed ID: 25475372
[TBL] [Abstract][Full Text] [Related]
29. FAK is a critical regulator of neuroblastoma liver metastasis.
Lee S; Qiao J; Paul P; O'Connor KL; Evers MB; Chung DH
Oncotarget; 2012 Dec; 3(12):1576-87. PubMed ID: 23211542
[TBL] [Abstract][Full Text] [Related]
30. The MYCN oncoprotein as a drug development target.
Lu X; Pearson A; Lunec J
Cancer Lett; 2003 Jul; 197(1-2):125-30. PubMed ID: 12880971
[TBL] [Abstract][Full Text] [Related]
31. Dihydropyrimidinase-like protein 3 expression is negatively regulated by MYCN and associated with clinical outcome in neuroblastoma.
Tan F; Wahdan-Alaswad R; Yan S; Thiele CJ; Li Z
Cancer Sci; 2013 Dec; 104(12):1586-92. PubMed ID: 24011394
[TBL] [Abstract][Full Text] [Related]
32. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
[TBL] [Abstract][Full Text] [Related]
33. Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma.
Chanthery YH; Gustafson WC; Itsara M; Persson A; Hackett CS; Grimmer M; Charron E; Yakovenko S; Kim G; Matthay KK; Weiss WA
Sci Transl Med; 2012 Jan; 4(115):115ra3. PubMed ID: 22218692
[TBL] [Abstract][Full Text] [Related]
34. Targeting focal adhesion kinase in neuroblastoma.
Gillory L; Beierle EA
Anticancer Agents Med Chem; 2010 Dec; 10(10):714-21. PubMed ID: 21269252
[TBL] [Abstract][Full Text] [Related]
35. MYCN repression of Lifeguard/FAIM2 enhances neuroblastoma aggressiveness.
Planells-Ferrer L; Urresti J; Soriano A; Reix S; Murphy DM; Ferreres JC; Borràs F; Gallego S; Stallings RL; Moubarak RS; Segura MF; Comella JX
Cell Death Dis; 2014 Sep; 5(9):e1401. PubMed ID: 25188511
[TBL] [Abstract][Full Text] [Related]
36. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.
Huang R; Cheung NK; Vider J; Cheung IY; Gerald WL; Tickoo SK; Holland EC; Blasberg RG
FASEB J; 2011 Dec; 25(12):4138-49. PubMed ID: 21856782
[TBL] [Abstract][Full Text] [Related]
37. Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma.
He J; Gu L; Zhang H; Zhou M
Cell Cycle; 2011 Sep; 10(17):2994-3002. PubMed ID: 21862876
[TBL] [Abstract][Full Text] [Related]
38. MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma.
Lau DT; Flemming CL; Gherardi S; Perini G; Oberthuer A; Fischer M; Juraeva D; Brors B; Xue C; Norris MD; Marshall GM; Haber M; Fletcher JI; Ashton LJ
Oncotarget; 2015 Jun; 6(17):15510-23. PubMed ID: 25860940
[TBL] [Abstract][Full Text] [Related]
39. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.
Song L; Ara T; Wu HW; Woo CW; Reynolds CP; Seeger RC; DeClerck YA; Thiele CJ; Sposto R; Metelitsa LS
J Clin Invest; 2007 Sep; 117(9):2702-12. PubMed ID: 17710228
[TBL] [Abstract][Full Text] [Related]
40. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.
Valentijn LJ; Koster J; Haneveld F; Aissa RA; van Sluis P; Broekmans ME; Molenaar JJ; van Nes J; Versteeg R
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19190-5. PubMed ID: 23091029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
